Quick Answer
Jasper Therapeutics, Inc. reported Total Assets of $35.78 million for the year ending 2025.
- Jasper Therapeutics, Inc. showed a decrease of -55.2% in Total Assets from 2024 to 2025.
- This data is from Jasper Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $101.79 million | Q2 2020: $101.60 million | Q3 2020: $101.32 million | Q1 2021: $100.96 million | Q2 2021: $100.55 million | Q3 2021: $107.21 million | Q1 2022: $80.55 million | Q2 2022: $70.37 million | Q3 2022: $59.11 million | Q1 2023: $138.76 million | Q2 2023: $124.17 million | Q3 2023: $110.41 million | Q1 2024: $125.96 million | Q2 2024: $113.93 million | Q3 2024: $99.41 million | Q1 2025: $57.60 million | Q2 2025: $46.47 million | Q3 2025: $57.47 million.
- Over the full 7 years of available data (2019 to 2025), Jasper Therapeutics, Inc.'s Total Assets has declined by 64.8%.
- Historical annual values: Fiscal year 2025: $35.78 million | Fiscal year 2024: $79.90 million | Fiscal year 2023: $94.89 million | Fiscal year 2022: $48.36 million | Fiscal year 2021: $93.65 million | Fiscal year 2020: $23.36 million | Fiscal year 2019: $101.69 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: